Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

详细信息    查看全文

• 作者：Clé ; mentine Sarkozy ; MD^a ; ^c ; Prof Alexandra Traverse-Glehen ; PhD^b ; ^c ; Prof Bertrand Coiffier ; PhD^a ; ^c ; ^{Bertrand.coiffier@chu-lyon.fr" class="auth_mail" title="E-mail the corresponding author}
• 刊名：The Lancet Oncology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：16
• 期：15
• 页码：e555-e567
• 全文大小：2370 K

文摘

Double-hit lymphoma (DHL) is a subgroup of aggressive lymphomas with both MYC and BCL2 gene rearrangements, characterised by a rapidly progressing clinical course that is refractory to aggressive treatment and short survival. Over time, the definition was modified and now includes diffuse large B-cell lymphoma (DLBCL) with MYC translocation combined with an additional translocation involving BCL2 or BCL6. Some cases that have a similar clinical course with concomitant overexpression of MYC or BCL2 proteins were recently characterised as immunohistochemical double-hit lymphomas (ie, double-protein-expression lymphomas [DPLs]). The clinical course of these DPLs is worse than so-called standard DLBCL but suggested by some studies to be slightly better than DHL, although there is overlap between the two categories. Present treatment does not allow cure or long-term survival in patients with genetic or immunohistochemical double-hit lymphomas, but several new drugs are being developed.